As managing director of India’s fifth largest pharmaceutical company, Zydus Cadila’s Sharvil Patel shares his insights on his impressive internationalization strategy with a special focus on the US where Zydus recently received permission to conduct Phase II clinical studies of Lipaglyn, the first drug to treat patients with nonalcoholic steatohepatitis (NASH).
Our global strategy is now to outlicense in many of the emerging markets to local large companies in countries such as Russia, Brazil and Colombia
